SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Texas Biotech (TXB)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Dauntless who wrote (95)3/4/1997 7:27:00 PM
From: NVestor   of 834
 
Thanks for input. I believe that monitoring coagulation does not entail
checking the platelet count.

I also did some investigating and discovered that in a local hospital a complete blood count with platelet count is around $70 and a platelet count alone is not much less.

My figure of $20 was just to calculate the difference in the total cost of treatment. It was also implying that the cost of heparin would be 0 just to compare savings that would accrue from tests not done.

I have also been told that although a drug may start out with a narrow focus companies frequently apply for other applications.
Perhaps the TXB product could replace heparin for routine use if it can be shown that the total cost of treatment is less and that the drug is safer. ...... Here's hoping!
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News